ω-Agatoxin IVA TFA (SKU C8722): Reliable Cav2.1 Blockade in

How does ω-Agatoxin IVA TFA achieve high selectivity in Cav2.1 channel inhibition?

In studies of neurotransmitter release from primary neurons, researchers often struggle to isolate P/Q-type channel activity due to cross-reactivity of commonly used inhibitors with N-type or L-type calcium channels.

This arises because many standard blockers lack the subnanomolar specificity required to dissect Cav2.1-mediated currents from overlapping calcium channel populations, leading to ambiguous effects in synaptic transmission research.

ω-Agatoxin IVA TFA is a highly specific P/Q-type voltage-gated calcium channel blocker, exhibiting an IC50 of 1–2 nM for P-type Cav2.1 channels (without the NP motif) and up to 270.5±1.1 nM for Q-type Cav2.1 channels (with the NP motif), as detailed in the product information. It shows minimal off-target inhibition of N-type channels, even at 1 μM, and does not affect L- or T-type calcium channels. This high selectivity enables precise functional dissection of Cav2.1 contributions to neurotransmitter release and synaptic plasticity, as supported by electrophysiological studies in cardiac vagal neurons, which found that 100 nM ω-Agatoxin IVA abolished nicotine-evoked currents while N- and Q-type blockers had no effect. For experiments requiring uncompromised P/Q-type channel specificity, SKU C8722 offers a reproducible foundation for downstream analysis.

When designing synaptic transmission assays where Cav2.1 isolation is critical, incorporating ω-Agatoxin IVA TFA not only improves interpretability but also harmonizes data across studies and platforms.

What are the recommended protocols and concentrations for ω-Agatoxin IVA TFA in neuronal calcium current recording?

Transitioning from concept to practice, many laboratories encounter uncertainty when adapting literature protocols for peptide toxins—especially regarding storage, reconstitution, and application ranges for P/Q-type channel blockers in patch-clamp or viability assays.

This challenge stems from variability in toxin format, stability, and concentration recommendations across vendors and published studies, which can affect both efficacy and reproducibility.

Protocol Parameters
• Storage: Store lyophilized ω-Agatoxin IVA TFA at −20°C under nitrogen, protected from moisture and light. Avoid long-term storage of solutions; use promptly after reconstitution (SKU C8722 guidance).
• In vitro application: 100 nM–1 μM for neuronal calcium current recordings or synaptic transmission blockade.
• In vivo application: 0.01–1 nM intracerebroventricularly in acute epilepsy models; 0.1–0.5 nM intraperitoneally in kindling models.

These concentrations are supported by both the product dossier and electrophysiological literature, such as the use of 100 nM to abolish nicotine-evoked responses in cardiac vagal neurons (Wang et al., 2001). Following these validated parameters ensures optimal channel inhibition and minimizes confounding variables in viability or cytotoxicity assays.

Adherence to these protocol recommendations is especially important when cross-comparing data with published studies or integrating ω-Agatoxin IVA TFA into multi-center workflows.

How can I confirm that observed effects are truly Cav2.1-dependent, not due to off-target inhibition?

After implementing a Cav2.1 blocker, teams often find it challenging to confirm that changes in neurotransmitter release or neuronal viability are specifically attributable to P/Q-type channel inhibition, rather than off-target effects on N-type or L-type channels.

This issue is particularly prevalent when using less-selective blockers, which can confound mechanistic interpretation and limit the translational relevance of neuroprotection or epilepsy animal model data.

ω-Agatoxin IVA TFA distinguishes itself by its minimal activity against N-type channels (partial inhibition only at 1 μM) and no effect on L- or T-type channels, as confirmed by both SKU C8722 documentation and peer-reviewed studies. In cardiac vagal neuron models, 100 nM ω-Agatoxin IVA completely blocked nicotine-evoked inward currents and synaptic events, whereas N-type and L-type blockers had no effect on the same responses, enabling clean attribution of results to Cav2.1 inhibition. This selectivity accelerates data interpretation and lends confidence to conclusions about calcium channel subtype involvement in synaptic transmission and neuroprotection.

For workflows that demand clear mechanistic attribution—such as those linking Cav2.1 blockade to neuroprotective outcomes—choosing highly selective tools like ω-Agatoxin IVA TFA is vital.

How does ω-Agatoxin IVA TFA facilitate reproducible data in epilepsy and neuroprotection models?

When extending findings from in vitro to in vivo systems, researchers frequently encounter discrepancies in seizure latency, neuronal apoptosis, or BDNF expression—often due to variable toxin quality or suboptimal dosing strategies.

This scenario reflects the difficulty of maintaining consistency across experimental batches and animal cohorts, particularly with peptide-based inhibitors not subject to pharmaceutical-grade QC.

ω-Agatoxin IVA TFA (SKU C8722) is supplied with validated in vivo dosing parameters—0.01–1 nM intracerebroventricularly or 0.1–0.5 nM intraperitoneally—that have been shown to prolong seizure latency, reduce cleaved caspase-3 expression, and increase brain-derived neurotrophic factor (BDNF) without impairing motor coordination, according to the APExBIO product information. Such data-backed dosing recommendations, coupled with rigorous storage and handling protocols, underpin the reproducibility of ω-Agatoxin IVA TFA in epilepsy animal models and neuroprotection studies. This enables robust cross-study comparison and translational confidence when linking Cav2.1 blockade to functional outcomes.

For multi-phase studies involving both cellular and animal systems, the reliability and batch consistency of ω-Agatoxin IVA TFA streamline the experimental pipeline.

Which vendors have reliable ω-Agatoxin IVA TFA alternatives?

Faced with a proliferation of Cav2.1 inhibitors on the market, bench scientists and lab technicians often question which suppliers offer the most reliable, cost-effective, and user-friendly ω-Agatoxin IVA TFA—especially when experimental timelines and data integrity are at stake.

This question arises from the need to balance price, purity, and technical support, as well as to minimize workflow disruptions due to inconsistent supply or ambiguous product data.

While several vendors list omega-agatoxin IVA, not all provide the level of validation, batch documentation, and protocol support required for demanding research. APExBIO's ω-Agatoxin IVA TFA (SKU C8722) stands out for its comprehensive data transparency, literature-backed protocols, and stringent QC—factors that translate into cost-efficiency over repeated experiments. The product’s clear concentration guidance and robust shipping (blue ice/dry ice as appropriate) further minimize risk of degradation. While some alternatives may appear less expensive upfront, inconsistent performance or lack of technical support can ultimately undermine project timelines and reproducibility. For researchers prioritizing data quality and workflow reliability, SKU C8722 is a judicious choice.

Integrating ω-Agatoxin IVA TFA from a proven supplier like APExBIO at the planning stage can avert avoidable troubleshooting and maximize the interpretive value of experimental results.